gilead sciences annual report matt paulson phd research scientist biology gilead foster city captain gileads softball team know takes win collaboration key applies research lab innovation dependent upon ability work team toward common goal discovering therapeutics lifethreatening diseasesat gilead greatest asset people individually employees talented dedicated professionals whose diverse experiences unique perspectives drive scientific innova tion excellence ana paula moita national sales manager gilead portugal spare time care dogs order help prepare life service people visual impairment feel real sense accomplishment knowing im contributing wellbeing people need feeling role sales manager working get physicians information need help better serve patientswe apply discipline focus everything qualities made us leader developing delivering new treatments hivaids lifethreatening diseases al ebrahim research scientist process development gilead alberta im kind person likes fix things takes time effort get right end satisfaction knowing something improved manufacturing plant rewarding part process chemistry every day step step im helping perfect process delivers important new treatments patients needcollectively employees share singular focus improving lives individ uals lifethreatening diseases regardless individuals live resources foundation everything makes gilead much business stockholders employees friends opening pages book introduce matt ana al three nearly employees gilead sciences individuals diverse roles backgrounds share singular focus focus every facilities nationwide october extension day help individuals around world ryan white care act established first time living unmet medical needs national goal screen five million people year developments help make hiv tests grew business substantially achiev ultimately treatment accessible gilead ing record revenues billion actively supporting programs diagnose link strengthening product portfolio pipeline care individuals living hiv hardest programs across four primary therapeutic areas hit often underserved communities believe able realize achievements looking facets hiv disease including view work business prevention gilead supporting ongoing trials community people working partner around world evaluate whether taking ship toward shared vision antiretroviral medicines could help protect atrisk individuals becoming infected hiv diseases focus affect tens millions potentially groundbreaking hiv prevention strategy individuals around world represent called preexposure prophylaxis prep first challenges physicians treat efficacy results prep expected left right gregg h alton executive vice president corporate medical affairs robin l washington patients families live senior vice president chief financial officer kevin young executive vice president commercial operations researchers collaborators like hiv chronic hepatitis b disease many john c martin phd chairman chief executive officer john f milligan phd president chief operating officer work find new ways combat individuals aware living norbert w bischofberger phd executive vice president research development chief scientific officer kristen metza senior vice president human resources virus left untreated chronic hepatitis b lead today million individuals around cirrhosis liver cancer pursuing efforts world living hivaids disease expand access information care com remains one gileads primary areas commer munities affected chronic hepatitis b addition received conditional approval liver disease serious cardiovascular respi cial research development focus disease disproportionate impact individ cayston treatment lung infections due ratory conditions cornerstone business united states uals asian descent demonstrated pseudomonas aeruginosa patients cystic percent hiv patients treatment longterm clinical trials potential fibrosis cf european union canada data hiv several compounds latestage receiving one gileads products oncedaily viread lower viral load thus decrease headtohead study cayston versus clinical trials new combination treatments fixeddose tablet atripla mostprescribed damage liver viread recommended tobramycin would support full approval horizon collaboration tibotec phar hiv treatment regimen truvada taken firstline treatment hbv guidelines territories expected toward middle maceuticals developing new oncedaily part combination therapy remained issued us european medical societies part year early cayston received ap singletablet regimen combining truvada prescribed hiv product europe continues gain share markets one proval united states australia cayston tibotecs nonnucleoside reverse transcriptase inhib truvada atripla became number one frequently prescribed oral antivirals represents first new inhaled antibiotic approved itor candidate rilpivirine approved product two brands respectively germany italy spain patients chronic hepatitis b patients cf decade would first alternative atripla united kingdom potential offer improved side effect profile cardiovascular front expanded port first therapy category respiratory dis hope file applications regulatory approval even commercial success recognize folio acquisition cv therapeutics ease tamiflu proved important compo product second half much done united states april brought us ranexa treatment nent global fight hn strain also excited developmentstage product least percent individuals living hiv chronic angina continued drive uptake influenza tamiflu developed combines investigational hiv integrase inhibitor approximately people unaware letairis pulmonary arterial hypertension gilead licensed f hoffmannla roche elvitegravir cobicistat formerly gs disease support contin pah disease affects approximately global commercialization partner investigational pharmacoenhancing boosting ued grow routine testing help diagnose patients worldwide also broadened efforts agent truvada creating new oncedaily individuals living hiv prevent late diagnoses support phase iv studies letairis beyond commercial products made signif fixeddose regimen known informally quad make virus harder treat prevent collaborating glaxosmithkline interna icant progress pipeline across phase ii studies quad cobicistat new infections tional eventdriven clinical trial called ambition research development programs hundreds standalone agent completed august us department veterans affairs study combination therapy versus monotherapy gilead scientists working create de pending discussions us food drug began offering routine voluntary hiv testing firstline treatment setting pah velop new compounds treatment hiv administration goal initiate phase iii studies middle year financial highlights continue develop treatments hepatitis c worldwide million individuals received nonalcoholic steatohepatitis nash including one gileads four hiv medications caspase inhibitor gs evaluated half patients live resource phase ii studies limited parts world reach patients partnered indian generic companies additional expertise resources gained develop generic versions hiv medications cv therapeutics acquisition distribute countries including india greatly improved ability advance research development treatments serious car gilead provides charitable contributions broad diovascular conditions unmet needs range nonprofit organizations evaluating potential ranexa nextgen gilead foundation also support efforts world eration late sodium current inhibitors number wide expand access disease education antiviral additional indications settings including improve infrastructure health services ambisome treatment patients diastolic heart gaap net income letairis gilead team diverse group people failure gs partial adenosine nongaap ranexa working laboratories offices communities ceptor agonist evaluated potential net income around world benefit guidance treatment diabetes leadership board directors net income product sales potential products available today welcomed kevin lofton president millions millions next generation development ceo catholic health initiatives realized patients access per woldolsen retired president human therapies health intercontinental division merck co board first foremost believe responsible pricing notes best way ensure broad access also stockholders employees nongaap net income excluded recognize many patients face challenges afford friends thank continued aftertax impact stockbased compen sation expenses million ing prescription medications advancing support belief mission part nongaap net income excluded access atripla patient assistance gileadsolutions gilead community one built past aftertax impact purchased iprd expense million incurred connection cayston access program assist patients years one continue acquisition navitas assets llcs assets related cicletanine business united states insurance grow bring new medications need aftertax impact stockbased compensa need additional financial help pay tion expenses million sincerely nongaap net income excluded medicines also assist patients insur aftertax impact acquisitionrelated expenses million aftertax impact ance coverage prescription medications restructuring expenses million unable bear full cost copayments aftertax impact stockbased compen sation expenses million january gilead adopted new ac counting guidance convertible senior notes retrospective basis accordingly john c martin phd gaap nongaap net income amounts chairman chief executive officer adjusted amounts previously reported reflect additional aftertax interest expense january gilead adopted new ac counting guidance joint ventures bristolmyers squibb retrospective basis accordingly operating cash flow amounts adjusted amounts total revenues operating cash flow previously reported reflect reclassifi millions millions cation operating cash flow financing cash flow forwardlooking statement annual report contains forwardlooking statements regarding dates expect initiate certain clinical studies potential certain product candidates dates anticipate receiving certain clinical trial results filing certain marketing authorizations statements predictions involve risks uncertainties actual results may differ materially please refer gileads annual report period ended december attached report risks uncertainties affecting gileads business gilead disclaims undertake obligation update revise forwardlooking statements report gileads focus areas hivaids liver disease cardiovascular disease respiratory disease past decade gilead played central chronic hepatitis b known silent killer despite enormous public attention invest saw significant developments role helping simplify treatment regimens many people unaware dis ment cardiovascular disease many serious forms efforts advance treatments serious respira hivaids portfolio single pill onceaday ease fail access timely medical care effective illness remain overlooked example tory ailments medicines includes fixeddose combination treatments including oncedaily medications people worldwide living pulmonary cystic fibrosis cf inherited disease affects tablets truvada atripla help opti viread hepsera critical helping delay arterial hypertension pah incurable disease people worldwide gileads cayston mize hiv therapy providing antiviral potency progressive damage liver caused virus lead heart failure gileads oncedaily letairis antibiotic treat lung infections due pseudo durability favorable safety tolerability annual meeting american asso used one three patients receiving monas aeruginosa patients cf granted low pill burden ciation study liver diseases aasld endothelinreceptor antagonist treatment conditional approval regulatory agencies gilead presented longterm data showing pah data released showed letairis recognizing benefits treatment guidelines european union canada early hepatitis b patients taking viread experience improved exercise capacity delayed clinical released us government european aids cayston received approval united states sustained viral suppression evidence worsening among diverse group pulmonary clinical society world health organization australia second investigational cf medication resistance treatment guidelines aasld hypertension patients recommend gileads hiv therapies preferred gs currently phase ii studies european association study components firstline treatment regimens expanded work therapeutic area liver recommend viread firstline additionally exploring potential significantly acquisition cv therapeutics hepatitis b treatment also focused developing hiv thera ambrisentan currently marketed letairis brought us ranexa treatment pies future several compounds treatment pah treat idiopathic pulmonary gilead also developing medications chronic angina also helped establish fully latestage clinical development continue fibrosis lifethreatening liver diseases gs integrated cardiovascular development regu work tibotec develop fixeddose combi daily caspase inhibitor development latory organization enhance gileads ability tamiflu continues represent important part nation truvada rilpivirine parallel potential treatment inflammatory fibrotic address serious cardiovascular metabolic respiratory portfolio product marketed advancing development quad regimen conditions hepatitis c nonalcoholic conditions unmet medical need worldwide f hoffmannla roche drew signifi combines truvada investigational steatohepatitis nash combination non cant attention year due role addressing integrase inhibitor elvitegravir pharma nucleoside polymerase inhibitor gs hn influenza pandemic tamiflu also remains coenhancing agent cobicistat protease inhibitor gs also moving important treatment prevention sea clinical studies treating hepatitis c sonal influenzamarketed products product pipeline hivaids indication partners gilead dedicated advancing care patients suffering life atripla hivaids bristolmyers squibb company threatening diseases worldwide research development programs currently efavirenz mgemtricitabine mg us western europe canada tenofovir disoproxil fumarate mg merck co inc rest world focus therapeutics potential treatment hivaids liver disease truvada hivaids japan tobacco inc japan serious cardiovascular respiratory conditions emtricitabine tenofovir disoproxil fumarate marketing emtriva hivaids japan tobacco inc japan applications emtricitabine candidate phase phase ii phase iii pending viread hivaids japan tobacco inc japan regadenoson tenofovir disoproxil fumarate stress agent myocardial perfusion imaging truvadarilpivirine liver disease indication partners fixeddose regimen hivaids viread chronic hepatitis b glaxosmithkline inc elvitegravir tenofovir disoproxil fumarate china integrase inhibitor hivaids ambrisentan hepsera chronic hepatitis b glaxosmithkline inc endothelin receptor antagonist idiopathic pulmonary fibrosis adefovir dipivoxil asia latin america integrase fixeddose regimen cardiovascular indication partners elvitegravircobicistattruvada hivaids cobicistat formerly gs lexiscan coronary vasodilation astellas pharma inc us pharmacoenhancer hivaids regadenoson injection gs polymerase inhibitor hepatitis c letairis pulmonary arterial glaxosmithkline inc ambrisentan hypertension outside us gs group caspase inhibitor nonalcoholic steatohepatitis ranexa chronic angina menarini group europe gs ranolazine caspase inhibitor hepatitis cfibrosis cicletanine antihypertensive pulmonary arterial hypertension respiratory indication partners aztreonam inhalation solution cayston cystic fibrosis antibiotic bronchiectasis aztreonam inhalation solution gs inhaled fosfomycintobramycin cystic fibrosis tamiflu influenza b f hoffmannla roche ltd ranolazine oseltamivir phosphate worldwide late sodium current inhibitor diastolic heart failure pending indication partners gs macugen neovascular wet osi pharmaceuticals inc us protease inhibitor hepatitis c pegaptanib sodium injection agerelated macular pfizer inc outside us gs degeneration ab adenosine antagonist pulmonary diseases vistide cmv retinitisaids gs cidofovir injection partial adenosine agonist diabeteshypertriglyceridemia gs ambisome severe fungal infections astellas pharma inc us canada epithelial sodium channel blocker cystic fibrosis amphotericin b liposome dainippon sumitomo injection pharma co ltd japan note include product candidates phase excludes research preclinical programsgilead cares gilead strive play part expanding supporting developing world access medications contributing research wellbeing communities live gilead actively supports developingcountry clinical work studies designed examine safety tolerability effectiveness vireadcontaining antiretroviral expanding access treatment regimens well studies examining use important component advancing patient viread prevention mothertochild trans care ensuring patients receive medi mission hiv among individuals hiv cations need even unable pay coinfected tuberculosis hepatitis b addition provide study drug placebo united states gileads patient assistance number studies supported centers copay support programs help uninsured disease control prevention national underinsured individuals obtain therapies institutes health public health leaders investigating whether viread truvada prevent developing countries gilead access program hiv transmission among atrisk uninfected adults provides viread truvada substantially reduced first efficacy data experimental strategy prices low lower middleincome coun called preexposure prophylaxis prep expect tries hardest hit hivaids epidemic critical ed later year component program gileads nonexclusive licensing partnerships drug manufacturers building healthy communities india able produce distribute quality lowcost generic versions medica gilead proud many active community volun tions developing world access teers company fields enthusiastic teams local efforts patients develop fund awarenessraising events aids ing world receiving therapies end liver heart cystic fibrosis walks many employees percent increase also volunteer time work community organizations international volunteer groups addition gilead offers significantly discounted pricing ambisome treatment visceral gilead foundation corpo leishmaniasis lifethreatening parasitic disease rate giving initiatives support programs resourcelimited settings also working united states around world working toward addressing hepatitis b treatment access improve health wellbeing underserved regions affected disease communities facing lauren temme linda koeppen two members gileads community group take time day volunteer local shelter setaicossa ngised yrwoh ngised corporate information board directors senior leadership team eric j topol md corporate headquarters director scripps translational john c martin phd john c martin phd gilead sciences inc science institute chairman chief executive officer chairman chief executive officer lakeside drive professor translational genomics gilead sciences foster city ca usa scripps research institute john f milligan phd chief academic officer james denny president chief operating officer scripps health lead independent director wwwgileadcom gilead sciences board directors norbert w bischofberger phd bernard wagner md executive vice president stockholder inquiries emeritus research professor paul berg phd research development pathology new york university inquiries stockholders nobel prize winner chemistry chief scientific officer medical center potential investors regarding cahill professor emeritus company always welcome stanford university gregg h alton health policy advisory board receive prompt response please executive vice president direct requests information john f cogan phd corporate medical affairs sir richard feachem kbe freng senior fellow hoover institution dscmed phd chairperson investor relations stanford university kevin young professor global health gilead sciences inc executive vice president university california san francisco lakeside drive etienne f davignon commercial operations university california berkeley foster city ca usa minister state director global health group ucsf vice chairman sueztractebel kristen metza senior vice president seth berkley md carla hills human resources founder president information regarding gilead also chair chief executive officer chief executive officer available wwwgileadcom hills company robin l washington international aids vaccine initiative senior vice president stock listing kevin e lofton chief financial officer ernest darkoh md mph mba president chief executive officer chairman founding partner gilead common stock traded catholic health initiatives scientific advisory board broadreach healthcare nasdaq global select stock market symbol gild joel r huff phd chairperson john w madigan michael v drake md retired vice president retired chairman chief executive chancellor annual meeting medicinal chemistry officer tribune company merck research laboratories university california irvine annual meeting stockholders held gordon e moore phd francis v chisari md david gollaher phd tuesday may westin retired chairman chief executive professor virology president chief executive officer san francisco airport hotel officer intel corporation california healthcare institute scripps research institute transfer agent registrar nicholas g moore robert shapiro phd peter b dervan phd communications concerning stock retired global chairman chairman sonecon llc bren professor chemistry transfer requirements lost certificates pricewaterhousecoopers california institute technology changes address richard j whitley md directed transfer agent richard j whitley md distinguished professor paul e klotman md distinguished professor loeb scholar chair pediatrics murray rosenberg professor bny mellon shareowner services loeb scholar chair pediatrics university alabama birmingham medicine chairman samuel washington boulevard university alabama birmingham bronfman department medicine jersey city nj usa per woldolsen mt sinai school medicine gayle edlund wilson retired president human health chair ralph parsons foundation intercontinental division wwwbnymelloncom gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas john w mellors md merck co inc unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide professor medicine chief equal opportunity employer per woldolsen headquartered foster city california gilead operations north america europe australia division infectious diseases retired president human health corporate secretary gilead sciences proud equal university pittsburgh intercontinental division opportunity employer extends ambisome cayston emtriva gilead gilead logo design hepsera letairis ranexa truvada viread vistide volibris school medicine gregg h alton merck co inc employment men women registered trademarks gilead sciences inc related companies atripla registered trademark bristolmyers squibb executive vice president culturally diverse backgrounds gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered trademark hoffmannla roche inc eugene r schiff md corporate medical affairs director emeritus leonard miller professor medicine environment respects individual differ sustiva registered trademark bristolmyers squibb pharma company macugen registered trademark eyetech inc gilead sciences board directors ences recognizes employee director schiff liver institute independent registered george p shultz phd director center liver diseases public accountants integral member company full us prescribing information gilead products available wwwgileadcom distinguished fellow workforce reflects values university miami hoover institution stanford university ernst young llp celebrates individuals school medicine palo alto california make growing team robert schooley md professor medicine head division infectious diseases vice chair department medicine university california san diego gilead sciences inc lakeside drive foster city ca f wwwgileadcom